{
    "hands_on_practices": [
        {
            "introduction": "A deep understanding of corneal dystrophies is rooted in genetics, as many are caused by heritable pathogenic variants. This exercise puts you in the role of a genetic counselor, tackling one of the most fundamental questions a family can ask: the risk of passing on a condition. By deriving the recurrence risk for a *TGFBI*-associated dystrophy, you will practice combining the principles of Mendelian segregation with the clinically crucial concept of incomplete penetrance, a scenario where possessing the gene does not guarantee expression of the disease .",
            "id": "4665934",
            "problem": "A couple presents for genetic counseling regarding the risk of corneal dystrophy in their future children. The father carries a known heterozygous pathogenic variant in the Transforming Growth Factor Beta-induced (TGFBI) gene, which is associated with autosomal dominant corneal stromal dystrophies. The mother has no personal or family history of corneal dystrophy and has tested negative for pathogenic variants in the TGFBI gene. Assume the following fundamental bases:\n\n- Autosomal dominant transmission implies that a single mutated allele is sufficient to confer susceptibility to the phenotype.\n- Mendelian segregation in meiosis yields equal probability of transmitting either allele from a heterozygote to offspring, assuming no segregation distortion.\n- Penetrance, denoted by $p$, is defined as the conditional probability that an individual with the disease genotype manifests the clinical phenotype.\n\nLet the father’s genotype at the relevant locus be $A a$, where $a$ is the pathogenic allele and $A$ is the normal allele, and let the mother’s genotype be $A A$. Assume there are no new mutations, no phenocopies, and independence between allele transmission and phenotypic expression given genotype. Given a penetrance of $p = 0.8$, derive from first principles the recurrence risk for a single offspring to be clinically affected by a TGFBI-associated corneal dystrophy. Express your final answer as a decimal fraction with no units.",
            "solution": "The problem statement is subjected to validation before a solution is attempted.\n\n### Step 1: Extract Givens\n-   **Genetic Condition:** Autosomal dominant corneal stromal dystrophy associated with the *Transforming Growth Factor Beta-induced* (*TGFBI*) gene.\n-   **Father's Genotype:** Heterozygous for a pathogenic variant, denoted as $Aa$, where $a$ is the pathogenic allele and $A$ is the normal allele.\n-   **Mother's Genotype:** No personal or family history of the condition and tested negative for pathogenic variants in *TGFBI*. Her genotype is denoted as $AA$.\n-   **Inheritance Principle 1:** Autosomal dominant transmission; a single mutated allele ($a$) is sufficient for susceptibility.\n-   **Inheritance Principle 2:** Mendelian segregation; a heterozygote ($Aa$) transmits either allele ($A$ or $a$) to an offspring with equal probability ($1/2$).\n-   **Penetrance Definition:** Penetrance, $p$, is the conditional probability that an individual with the disease genotype manifests the clinical phenotype.\n-   **Specific Value:** The penetrance is given as $p = 0.8$.\n-   **Assumptions:**\n    -   No new mutations (de novo mutations).\n    -   No phenocopies (individuals with genotype $AA$ do not exhibit the phenotype).\n    -   Independence between allele transmission and phenotypic expression, given the genotype.\n-   **Objective:** Derive the recurrence risk for a single offspring to be clinically affected.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the established criteria.\n-   **Scientifically Grounded:** The problem is firmly rooted in the principles of Mendelian genetics. *TGFBI*-associated corneal dystrophies are well-documented autosomal dominant disorders, and the concepts of heterozygosity, penetrance, and recurrence risk are central to medical genetics. The scenario is a standard and realistic case in genetic counseling.\n-   **Well-Posed:** All necessary information is provided. The genotypes of the parents, the mode of inheritance, the penetrance, and relevant simplifying assumptions (no new mutations, no phenocopies) are explicitly stated. This allows for the calculation of a unique and meaningful probability.\n-   **Objective:** The problem is stated using precise, standard scientific terminology. There are no subjective or ambiguous statements.\n\nThe problem does not violate any of the invalidity criteria. It is scientifically sound, complete, consistent, and well-posed.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. A solution will be derived from first principles.\n\n### Derivation of Recurrence Risk\nThe objective is to calculate the probability that a single offspring of this couple will be clinically affected by the *TGFBI*-associated corneal dystrophy. This probability is the recurrence risk.\n\nLet $E_{\\text{affected}}$ be the event that an offspring is clinically affected.\nLet $G_{Aa}$ be the event that the offspring inherits the genotype $Aa$.\nLet $G_{AA}$ be the event that the offspring inherits the genotype $AA$.\n\nThe law of total probability allows us to express the total probability of being affected as the sum of probabilities conditioned on the possible genotypes of the offspring:\n$$P(E_{\\text{affected}}) = P(E_{\\text{affected}} | G_{Aa}) P(G_{Aa}) + P(E_{\\text{affected}} | G_{AA}) P(G_{AA})$$\n\nThe derivation proceeds by determining each term in this expression.\n\n**1. Probability of Offspring Genotypes:**\nWe determine the probabilities of the offspring's possible genotypes ($P(G_{Aa})$ and $P(G_{AA})$) based on the parental genotypes and the principle of Mendelian segregation.\n-   Father's genotype: $Aa$. He transmits allele $A$ with probability $P(A_{\\text{father}}) = 1/2$ and allele $a$ with probability $P(a_{\\text{father}}) = 1/2$.\n-   Mother's genotype: $AA$. She transmits allele $A$ with probability $P(A_{\\text{mother}}) = 1$.\n\nThe possible genotypes for the offspring are derived from the combinations of alleles transmitted by each parent:\n-   The offspring has genotype $Aa$ if they receive allele $a$ from the father and allele $A$ from the mother. The probability of this event is:\n    $$P(G_{Aa}) = P(a_{\\text{father}}) \\times P(A_{\\text{mother}}) = \\frac{1}{2} \\times 1 = \\frac{1}{2}$$\n-   The offspring has genotype $AA$ if they receive allele $A$ from the father and allele $A$ from the mother. The probability of this event is:\n    $$P(G_{AA}) = P(A_{\\text{father}}) \\times P(A_{\\text{mother}}) = \\frac{1}{2} \\times 1 = \\frac{1}{2}$$\n\n**2. Conditional Probability of Being Affected (Penetrance and Phenocopy):**\nNext, we determine the conditional probabilities of being clinically affected, given a specific genotype.\n-   $P(E_{\\text{affected}} | G_{Aa})$: This is the probability that an individual with the pathogenic genotype $Aa$ will manifest the clinical phenotype. By definition, this is the penetrance of the gene, $p$.\n    $$P(E_{\\text{affected}} | G_{Aa}) = p$$\n-   $P(E_{\\text{affected}} | G_{AA})$: This is the probability that an individual with the normal genotype $AA$ will manifest the clinical phenotype. The problem states to assume \"no phenocopies,\" which means that the phenotype only occurs in the presence of the pathogenic genotype. Therefore, this probability is zero.\n    $$P(E_{\\text{affected}} | G_{AA}) = 0$$\n\n**3. Calculation of Total Probability (Recurrence Risk):**\nNow, we substitute the derived probabilities back into the law of total probability equation:\n$$P(E_{\\text{affected}}) = (p) \\times P(G_{Aa}) + (0) \\times P(G_{AA})$$\n$$P(E_{\\text{affected}}) = p \\times \\frac{1}{2} + 0 \\times \\frac{1}{2}$$\n$$P(E_{\\text{affected}}) = \\frac{p}{2}$$\n\nThis symbolic expression represents the recurrence risk for any autosomal dominant condition with penetrance $p$ transmitted from a single heterozygous parent to an offspring with a homozygous normal parent.\n\n**4. Final Numerical Calculation:**\nThe problem provides the specific value for penetrance, $p = 0.8$. Substituting this value into our derived formula gives the final answer.\n$$P(E_{\\text{affected}}) = \\frac{0.8}{2} = 0.4$$\n\nThus, the recurrence risk for a single offspring to be clinically affected by the *TGFBI*-associated corneal dystrophy is $0.4$.",
            "answer": "$$\n\\boxed{0.4}\n$$"
        },
        {
            "introduction": "Moving from genetic cause to clinical effect, we now turn to the quantitative assessment of corneal health. Specular microscopy is the gold standard for evaluating the corneal endothelium, a single layer of cells vital for maintaining corneal clarity and one that is implicated in dystrophies like Fuchs'. This practice will guide you through the process of analyzing raw data from a specular micrograph, translating cell counts and measurements into the key clinical metrics of endothelial cell density (ECD), polymegathism, and pleomorphism to construct a comprehensive picture of endothelial integrity .",
            "id": "4665970",
            "problem": "A central corneal specular microscopy study is performed in a patient with suspected endothelial degeneration. You are provided with three non-overlapping calibrated fields, each overlaid by a square grid of known geometry. Endothelial cells were counted in each field using the standard inclusion–exclusion rule (include cells touching the top and left borders; exclude those touching the bottom and right borders). For morphometric assessment, a masked observer measured the planimetric areas of a random sample of cells from these fields.\n\nUse only foundational definitions:\n- Endothelial cell density (ECD) is defined as $\\text{ECD} = \\frac{N}{A}$, where $N$ is the number of endothelial cells and $A$ is the examined area.\n- Polymegathism is quantified by the coefficient of variation (CV) of cell area, defined as $\\text{CV} = \\frac{s}{\\bar{A}}$, where $s$ is the sample standard deviation of cell area and $\\bar{A}$ is the sample mean cell area.\n- Pleomorphism is summarized by the hexagonality fraction $H$, the fraction of cells that are hexagonal.\n\nFor this experiment:\n- Field calibrations (each small grid square has side length $25\\,\\mu\\text{m}$):\n  - Field $1$: $8 \\times 8$ small squares; corrected cell count $N_{1} = 100$.\n  - Field $2$: $10 \\times 10$ small squares; corrected cell count $N_{2} = 155$.\n  - Field $3$: $6 \\times 6$ small squares; corrected cell count $N_{3} = 56$.\n- Morphometry (random sample across the same region): sample mean cell area $\\bar{A} = 400\\,\\mu\\text{m}^2$; sample standard deviation $s = 160\\,\\mu\\text{m}^2$; among $100$ sampled cells, $48$ are hexagonal, so $H = \\dfrac{48}{100}$.\n- Use the reference density $E_{0} = 2500\\,\\text{cells}/\\mathrm{mm}^2$ to scale ECD.\n\nDefine the morphology-adjusted endothelial integrity index $\\text{MEI}$ by\n$$\n\\text{MEI} = \\left( \\dfrac{\\text{ECD}}{E_{0}} \\right) \\left( \\dfrac{H}{\\text{CV}} \\right).\n$$\n\nTasks:\n1. Compute each field area $A_{i}$ from the grid, then compute the total area $A_{\\text{tot}}$ and total cell count $N_{\\text{tot}}$, and from these compute $\\text{ECD}$ in $\\text{cells}/\\mathrm{mm}^{2}$.\n2. Compute $\\text{CV}$ from the given morphometric summary, and compute $H$ as a fraction.\n3. Compute $\\text{MEI}$ using the above definition.\n\nRound your final $\\text{MEI}$ to four significant figures. Express the final index as a pure number (dimensionless).",
            "solution": "The problem statement is first subjected to validation. It is found to be scientifically grounded, well-posed, and objective. The parameters described—endothelial cell density ($\\text{ECD}$), coefficient of variation of cell area ($\\text{CV}$), and hexagonality ($H$)—are standard metrics in the analysis of corneal endothelium via specular microscopy. The definitions provided, $\\text{ECD} = \\frac{N}{A}$ and $\\text{CV} = \\frac{s}{\\bar{A}}$, are correct. The provided numerical values for cell counts, areas, and morphometric statistics are within a plausible range for a patient with suspected endothelial degeneration. The problem is self-contained, providing all necessary data and a clear, albeit synthetic, formula for the final index ($\\text{MEI}$). As no flaws are identified, the problem is deemed valid, and a full solution is presented below.\n\nThe calculation is performed in three sequential tasks as requested.\n\n**Task 1: Compute Endothelial Cell Density ($\\text{ECD}$)**\n\nThe total endothelial cell density is determined by pooling the data from the three non-overlapping fields. First, the area of each field is calculated. The side length of a single small grid square is given as $l=25\\,\\mu\\text{m}$. The area of one such square is:\n$$A_{\\text{sq}} = l^2 = (25\\,\\mu\\text{m})^2 = 625\\,\\mu\\text{m}^2$$\n\nThe areas of the three fields ($A_1$, $A_2$, $A_3$) are determined by multiplying the number of squares in each grid by $A_{\\text{sq}}$:\n- Field $1$: The grid is $8 \\times 8$, containing $64$ squares.\n$$A_1 = 64 \\times A_{\\text{sq}} = 64 \\times 625\\,\\mu\\text{m}^2 = 40000\\,\\mu\\text{m}^2$$\n- Field $2$: The grid is $10 \\times 10$, containing $100$ squares.\n$$A_2 = 100 \\times A_{\\text{sq}} = 100 \\times 625\\,\\mu\\text{m}^2 = 62500\\,\\mu\\text{m}^2$$\n- Field $3$: The grid is $6 \\times 6$, containing $36$ squares.\n$$A_3 = 36 \\times A_{\\text{sq}} = 36 \\times 625\\,\\mu\\text{m}^2 = 22500\\,\\mu\\text{m}^2$$\n\nThe total examined area, $A_{\\text{tot}}$, is the sum of the individual field areas:\n$$A_{\\text{tot}} = A_1 + A_2 + A_3 = 40000\\,\\mu\\text{m}^2 + 62500\\,\\mu\\text{m}^2 + 22500\\,\\mu\\text{m}^2 = 125000\\,\\mu\\text{m}^2$$\n\nThe total cell count, $N_{\\text{tot}}$, is the sum of the corrected counts from each field: $N_1 = 100$, $N_2 = 155$, and $N_3 = 56$.\n$$N_{\\text{tot}} = N_1 + N_2 + N_3 = 100 + 155 + 56 = 311$$\n\nThe overall $\\text{ECD}$ is computed using the total count and total area.\n$$\\text{ECD} = \\frac{N_{\\text{tot}}}{A_{\\text{tot}}} = \\frac{311}{125000} \\, \\frac{\\text{cells}}{\\mu\\text{m}^2}$$\nThe result must be converted to units of $\\text{cells}/\\mathrm{mm}^2$. The conversion factor is derived from $1\\,\\text{mm} = 10^3\\,\\mu\\text{m}$, which gives $1\\,\\text{mm}^2 = (10^3)^2\\,\\mu\\text{m}^2 = 10^6\\,\\mu\\text{m}^2$:\n$$\\text{ECD} = \\left(\\frac{311}{125000} \\, \\frac{\\text{cells}}{\\mu\\text{m}^2}\\right) \\times \\left(\\frac{10^6\\,\\mu\\text{m}^2}{1\\,\\mathrm{mm}^2}\\right) = \\frac{311 \\times 10^6}{125000} \\, \\frac{\\text{cells}}{\\mathrm{mm}^2}$$\n$$\\text{ECD} = \\frac{311 \\times 1000}{125} \\, \\frac{\\text{cells}}{\\mathrm{mm}^2} = 311 \\times 8 \\, \\frac{\\text{cells}}{\\mathrm{mm}^2} = 2488 \\, \\frac{\\text{cells}}{\\mathrm{mm}^2}$$\n\n**Task 2: Compute Morphometric Parameters $\\text{CV}$ and $H$**\n\nThe coefficient of variation of cell area ($\\text{CV}$), a measure of polymegathism, is calculated using the provided sample mean cell area, $\\bar{A} = 400\\,\\mu\\text{m}^2$, and sample standard deviation, $s = 160\\,\\mu\\text{m}^2$.\n$$\\text{CV} = \\frac{s}{\\bar{A}} = \\frac{160\\,\\mu\\text{m}^2}{400\\,\\mu\\text{m}^2} = 0.4$$\nThe hexagonality fraction ($H$), a measure of pleomorphism, is the fraction of cells in the sample that are hexagonal. From the data, $48$ cells out of $100$ were hexagonal.\n$$H = \\frac{48}{100} = 0.48$$\nBoth $\\text{CV}$ and $H$ are dimensionless quantities.\n\n**Task 3: Compute the Morphology-adjusted Endothelial Integrity Index ($\\text{MEI}$)**\n\nThe $\\text{MEI}$ is calculated using the defined formula:\n$$\\text{MEI} = \\left( \\frac{\\text{ECD}}{E_{0}} \\right) \\left( \\frac{H}{\\text{CV}} \\right)$$\nWe substitute the previously computed values and the given reference density, $E_0 = 2500\\,\\text{cells}/\\mathrm{mm}^2$:\n- $\\text{ECD} = 2488\\,\\text{cells}/\\mathrm{mm}^2$\n- $E_0 = 2500\\,\\text{cells}/\\mathrm{mm}^2$\n- $\\text{CV} = 0.4$\n- $H = 0.48$\n\nThe calculation proceeds as follows:\n$$\\text{MEI} = \\left( \\frac{2488}{2500} \\right) \\left( \\frac{0.48}{0.4} \\right)$$\n$$\\text{MEI} = (0.9952) \\times (1.2) = 1.19424$$\nThe problem requires the final answer to be rounded to four significant figures. The fifth significant digit is $2$, so we round down.\n$$\\text{MEI} \\approx 1.194$$\nThe index is a dimensionless pure number, as all units cancel.",
            "answer": "$$\n\\boxed{1.194}\n$$"
        },
        {
            "introduction": "Finally, we apply our quantitative skills to the principles of therapy, focusing on corneal collagen cross-linking (CXL), a cornerstone treatment for progressive ectatic degenerations like keratoconus. This exercise demonstrates the law of photochemical reciprocity, a foundational principle stating that a specific biological effect is determined by the total energy dose, irrespective of the rate of delivery. By calculating the total energy for various clinical protocols, you will understand how accelerated CXL protocols can achieve the same therapeutic dose as the original Dresden protocol in a fraction of the time, a key insight into modern clinical practice .",
            "id": "4665951",
            "problem": "A patient with progressive keratoconus (a corneal ectatic degeneration) is scheduled for epithelium-off riboflavin–Ultraviolet A (UVA) corneal collagen cross-linking (CXL). In the context of photochemical tissue interactions, assume the following foundational facts: irradiance $I$ is energy per unit area per unit time, cumulative energy per unit area $E$ delivered to a surface equals the time integral of irradiance incident on that surface, and for constant irradiance over a time interval the integral reduces to a product. Consider that the beam profile is spatially uniform over the intended treatment zone and that $I$ is constant during each protocol.\n\nUsing these bases, derive the cumulative energy per unit area delivered for constant-irradiance exposures and then compute $E$ for the following four clinically used UVA protocols:\n- Dresden protocol: $I = 3\\,\\text{mW/cm}^2$ for $t = 30\\,\\text{min}$ (continuous exposure),\n- Accelerated protocol A: $I = 9\\,\\text{mW/cm}^2$ for $t = 10\\,\\text{min}$,\n- Accelerated protocol B: $I = 18\\,\\text{mW/cm}^2$ for $t = 5\\,\\text{min}$,\n- Accelerated protocol C: $I = 30\\,\\text{mW/cm}^2$ for $t = 3\\,\\text{min}$.\n\nAll irradiances are incident at the corneal surface. Express the cumulative energy per unit area in joules per square centimeter ($\\text{J/cm}^2$). Provide your answer as a single row matrix ordered as [Dresden, $9\\,\\text{mW/cm}^2$ for $10\\,\\text{min}$, $18\\,\\text{mW/cm}^2$ for $5\\,\\text{min}$, $30\\,\\text{mW/cm}^2$ for $3\\,\\text{min}$], and round each entry to three significant figures. Assume $1\\,\\text{mW/cm}^2 = 10^{-3}\\,\\text{W/cm}^2$ and $1\\,\\text{min} = 60\\,\\text{s}$.",
            "solution": "The problem requires the derivation of the formula for cumulative energy per unit area, $E$, under constant irradiance, and its subsequent calculation for four distinct clinical protocols for corneal collagen cross-linking.\n\nFirst, we validate the problem statement. The problem provides a clear, scientifically grounded physical scenario based on established medical procedures and fundamental physics. It defines all terms, provides all necessary constants and data, and specifies the required output format. The problem is self-contained, consistent, and well-posed. There are no identifiable flaws.\n\nNow, we proceed with the solution.\n\nThe problem defines irradiance, $I$, as energy per unit area per unit time. The cumulative energy per unit area, $E$ (also known as fluence in this context), is defined as the time integral of the irradiance incident on a surface. For a time-varying irradiance $I(t)$ over a total exposure duration of $T$, this is expressed as:\n$$E = \\int_0^T I(t) \\, dt$$\nThe problem states that for each protocol, the irradiance $I$ is constant over the exposure time interval. This means $I(t)$ is a constant, $I$, which can be factored out of the integral:\n$$E = I \\int_0^T dt$$\nEvaluating the simple integral yields the relationship between cumulative energy, constant irradiance, and exposure time:\n$$E = I \\cdot [t]_0^T = I \\cdot (T - 0) = I \\cdot T$$\nThis equation, $E = I \\cdot T$, is the derived formula for cumulative energy per unit area delivered by a constant-irradiance exposure. This relationship is a manifestation of the Bunsen-Roscoe law of photochemical reciprocity, which posits that the photochemical effect is proportional to the total energy dose delivered, irrespective of the rate (irradiance) at which it is delivered.\n\nThe task is to compute $E$ in units of joules per square centimeter ($\\text{J/cm}^2$). The given values for irradiance $I$ are in milliwatts per square centimeter ($\\text{mW/cm}^2$), and the time $T$ is in minutes ($\\text{min}$). We must convert these to a consistent system of units. The problem provides the necessary conversion factors:\n$$1\\,\\text{mW/cm}^2 = 10^{-3}\\,\\text{W/cm}^2$$\n$$1\\,\\text{min} = 60\\,\\text{s}$$\nA watt ($\\text{W}$) is defined as one joule per second ($1\\,\\text{W} = 1\\,\\text{J/s}$). Therefore, the product of irradiance in $\\text{W/cm}^2$ and time in $\\text{s}$ will have units of $\\text{J/cm}^2$:\n$$[\\text{W/cm}^2] \\times [\\text{s}] = \\left(\\frac{\\text{J}}{\\text{s} \\cdot \\text{cm}^2}\\right) \\times \\text{s} = \\frac{\\text{J}}{\\text{cm}^2}$$\nWe now apply the formula $E = I \\cdot T$ to each of the four specified protocols.\n\n1.  **Dresden protocol**:\n    Given irradiance $I_1 = 3\\,\\text{mW/cm}^2$ and exposure time $T_1 = 30\\,\\text{min}$.\n    First, we convert the units to $\\text{W/cm}^2$ and $\\text{s}$:\n    $$I_1 = 3\\,\\text{mW/cm}^2 = 3 \\times 10^{-3}\\,\\text{W/cm}^2$$\n    $$T_1 = 30\\,\\text{min} \\times \\frac{60\\,\\text{s}}{1\\,\\text{min}} = 1800\\,\\text{s}$$\n    The cumulative energy per unit area, $E_1$, is:\n    $$E_1 = I_1 \\cdot T_1 = (3 \\times 10^{-3}\\,\\text{W/cm}^2) \\times (1800\\,\\text{s}) = 5.4\\,\\text{J/cm}^2$$\n\n2.  **Accelerated protocol A**:\n    Given irradiance $I_2 = 9\\,\\text{mW/cm}^2$ and exposure time $T_2 = 10\\,\\text{min}$.\n    Converting units:\n    $$I_2 = 9\\,\\text{mW/cm}^2 = 9 \\times 10^{-3}\\,\\text{W/cm}^2$$\n    $$T_2 = 10\\,\\text{min} \\times \\frac{60\\,\\text{s}}{1\\,\\text{min}} = 600\\,\\text{s}$$\n    The cumulative energy per unit area, $E_2$, is:\n    $$E_2 = I_2 \\cdot T_2 = (9 \\times 10^{-3}\\,\\text{W/cm}^2) \\times (600\\,\\text{s}) = 5.4\\,\\text{J/cm}^2$$\n\n3.  **Accelerated protocol B**:\n    Given irradiance $I_3 = 18\\,\\text{mW/cm}^2$ and exposure time $T_3 = 5\\,\\text{min}$.\n    Converting units:\n    $$I_3 = 18\\,\\text{mW/cm}^2 = 18 \\times 10^{-3}\\,\\text{W/cm}^2$$\n    $$T_3 = 5\\,\\text{min} \\times \\frac{60\\,\\text{s}}{1\\,\\text{min}} = 300\\,\\text{s}$$\n    The cumulative energy per unit area, $E_3$, is:\n    $$E_3 = I_3 \\cdot T_3 = (18 \\times 10^{-3}\\,\\text{W/cm}^2) \\times (300\\,\\text{s}) = 5.4\\,\\text{J/cm}^2$$\n\n4.  **Accelerated protocol C**:\n    Given irradiance $I_4 = 30\\,\\text{mW/cm}^2$ and exposure time $T_4 = 3\\,\\text{min}$.\n    Converting units:\n    $$I_4 = 30\\,\\text{mW/cm}^2 = 30 \\times 10^{-3}\\,\\text{W/cm}^2$$\n    $$T_4 = 3\\,\\text{min} \\times \\frac{60\\,\\text{s}}{1\\,\\text{min}} = 180\\,\\text{s}$$\n    The cumulative energy per unit area, $E_4$, is:\n    $$E_4 = I_4 \\cdot T_4 = (30 \\times 10^{-3}\\,\\text{W/cm}^2) \\times (180\\,\\text{s}) = 5.4\\,\\text{J/cm}^2$$\n\nAll four protocols result in the same cumulative energy per unit area of $5.4\\,\\text{J/cm}^2$. This value is the standard total energy dose for corneal cross-linking. The problem requires rounding each entry to three significant figures. The value $5.4$ must be written as $5.40$ to satisfy this requirement. The final answer is to be presented as a single row matrix containing these four values in the specified order.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n5.40 & 5.40 & 5.40 & 5.40\n\\end{pmatrix}\n}\n$$"
        }
    ]
}